Becton Dickinson & Co

Discover how China’s new drug‑approval rules, pricing changes, and IP shifts give foreign pharma, especially BD, a first‑mover edge—and what risks they must manage in the 2024 Beijing roundtable.

BDX Q2 2026 results: net loss amid higher integration costs but positive adjusted earnings, 3.6 % revenue growth, new CFO, and a bullish EPS outlook amid shifting reimbursement models.

BD’s latest report shows solid dividend returns, governance cuts, and a new CentroVena One catheter system poised to meet CMS bundled payments and boost profitability.

BD wins inaugural HIRC Member Choice Awards for Transparency, Resiliency, and Partnership – showcasing unmatched supply‑chain excellence and customer‑centric resilience.

BDX’s latest executive ownership filing and AI‑driven Pyxis Pro & Incada dispensing systems roll‑out highlight the company’s focus on transparency, safety and cost‑efficient, data‑powered clinical solutions for hospitals in Europe.

Institutional investors sold 28,818 Becton Dickinson shares on April 4, 2026, with no disclosed rationale—illustrating routine portfolio rebalancing amid a liquid market.

BD’s BDS spin‑off to Waters delivers clear, unaudited financials and strategic focus, enhancing regulatory compliance and investor insight.

BD launches AI‑driven Pyxis Pro and Incada platforms in Europe—boosting medication safety, reducing waste by 20%, and meeting GDPR while opening a €4 billion market.

Insightful Becton Dickinson insider sales and institutional buying signal balanced confidence, regulatory compliance, and growth prospects for investors.

BD’s Revello covered stent earns CE mark, offering a low‑profile, ultrathin PTFE design that tackles restenosis in iliac arteries and expands the company’s EU vascular portfolio.